KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to $3.1 billion.

  • Boston Scientific's Receivables - Net rose 1466.07% to $3.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.1 billion, marking a year-over-year increase of 1466.07%. This contributed to the annual value of $3.1 billion for FY2025, which is 1466.07% up from last year.
  • Latest data reveals that Boston Scientific reported Receivables - Net of $3.1 billion as of Q4 2025, which was up 1466.07% from $3.0 billion recorded in Q3 2025.
  • In the past 5 years, Boston Scientific's Receivables - Net ranged from a high of $3.1 billion in Q4 2025 and a low of $1.7 billion during Q1 2021
  • Moreover, its 5-year median value for Receivables - Net was $2.2 billion (2023), whereas its average is $2.3 billion.
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 414.66% in 2021, then skyrocketed by 1725.07% in 2024.
  • Over the past 5 years, Boston Scientific's Receivables - Net (Quarter) stood at $1.9 billion in 2021, then rose by 10.23% to $2.1 billion in 2022, then rose by 12.46% to $2.3 billion in 2023, then rose by 14.07% to $2.7 billion in 2024, then rose by 14.66% to $3.1 billion in 2025.
  • Its last three reported values are $3.1 billion in Q4 2025, $3.0 billion for Q3 2025, and $2.9 billion during Q2 2025.